The study included: 67,769 people with type 2 diabetes and 17,604 people with overweight or obesity and cardiovascular disease but without diabetes
Holst today to try to really understand exactly the mechanism of how these GLP-1 medicines work in order to understand why so many people are taking them for diseases and afflictions far beyond diabetes, which is what the GLP-1s were first intended for
Blocking was carried out in blocking solution (42 ml PTx.2, 3 ml donkey serum, 5 ml dimethylsulfoxide, 0.02% sodium azide) at 37 C for 2 days
Activation of the NTS MHb IPN circuit by GLP-1 or its analogues suppresses nicotine intake and abolishes reward-related responses, while genetic or pharmacological disruption of this pathway enhances consumption
Verma S, Goldenberg RM, Bhatt DL, Farkouh ME, Quan A, Teoh H, Connelly KA, Leiter LA, Friedrich JO